RPS6KB1 and breast carcinoma: We found only one study in which pre-treatment with everolimus, a clinical mTOR inhibitor, radio-sensitised MDA-MB-231 and MCF7 breast cancer cells by blocking radiation-induced mTOR-S6K1 signalling18.